Cargando…
Realising the broader value of vaccines in the UK
Many health technology assessment (HTA) agencies limit their assessments of vaccines to the health benefits for the vaccinated individual, the costs associated with vaccine administration and the disease avoided. However, because the value of vaccines tends to accrue to a large extent beyond the vac...
Autores principales: | Brassel, Simon, Neri, Margherita, O'Neill, Phill, Steuten, Lotte |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8099625/ https://www.ncbi.nlm.nih.gov/pubmed/33997762 http://dx.doi.org/10.1016/j.jvacx.2021.100096 |
Ejemplares similares
-
PIN62 Recognising the broader value of vaccines in HTA: ready for prime time?
por: Brassel, S., et al.
Publicado: (2021) -
Towards a Broader Assessment of Value in Vaccines: The BRAVE Way Forward
por: Bell, Eleanor, et al.
Publicado: (2021) -
Vaccine-Preventable Hospitalisations from Seasonal Respiratory Diseases: What Is Their True Value?
por: Neri, Margherita, et al.
Publicado: (2023) -
Does NICE influence the adoption and uptake of generics in the UK?
por: Serra-Sastre, Victoria, et al.
Publicado: (2020) -
Estimates of the Global Burden of COVID-19 and the Value of Broad and Equitable Access to COVID-19 Vaccines
por: Bell, Eleanor, et al.
Publicado: (2022)